
Arcus Biosciences Inc
NYSE:RCUS

Intrinsic Value
The intrinsic value of one
RCUS
stock under the Base Case scenario is
15.68
USD.
Compared to the current market price of 9.02 USD,
Arcus Biosciences Inc
is
Undervalued by 42%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Arcus Biosciences Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Arcus Biosciences Inc
Balance Sheet Decomposition
Arcus Biosciences Inc
Current Assets | 1B |
Cash & Short-Term Investments | 978m |
Receivables | 25m |
Other Current Assets | 13m |
Non-Current Assets | 134m |
Long-Term Investments | 14m |
PP&E | 112m |
Other Non-Current Assets | 8m |
Free Cash Flow Analysis
Arcus Biosciences Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Arcus Biosciences Inc
Revenue
|
258m
USD
|
Operating Expenses
|
-568m
USD
|
Operating Income
|
-310m
USD
|
Other Expenses
|
27m
USD
|
Net Income
|
-283m
USD
|
RCUS Profitability Score
Profitability Due Diligence
Arcus Biosciences Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

Score
Arcus Biosciences Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
RCUS Solvency Score
Solvency Due Diligence
Arcus Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Score
Arcus Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RCUS Price Targets Summary
Arcus Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
RCUS
is 30.97 USD
with a low forecast of 14.14 USD and a high forecast of 48.3 USD.
Dividends
Current shareholder yield for RCUS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RCUS
stock under the Base Case scenario is
15.68
USD.
Compared to the current market price of 9.02 USD,
Arcus Biosciences Inc
is
Undervalued by 42%.